Tau or neurofilament light—Which is the more suitable biomarker for Huntington’s disease?
Previous studies have suggested cerebrospinal fluid (CSF) levels of neurofilament light (NFL) and total tau are elevated in Huntington's disease (HD) and may be used as markers of disease stage. Biomarkers are needed due to the slow disease progression and the limitations of clinical assessment...
Saved in:
| Published in | PloS one Vol. 12; no. 2; p. e0172762 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
27.02.2017
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Previous studies have suggested cerebrospinal fluid (CSF) levels of neurofilament light (NFL) and total tau are elevated in Huntington's disease (HD) and may be used as markers of disease stage. Biomarkers are needed due to the slow disease progression and the limitations of clinical assessment. This study aims to validate the role of NFL and tau as biomarkers in HD.
CSF was obtained from a cohort of HD patients and premanifest HD-mutation carriers. Unified Huntington's Disease Rating Scale (UHDRS) testing was performed on all subjects at the time of sampling. NFL and tau concentrations were determined by ELISA. Spearman correlations were calculated with R version 3.2.3.
11 premanifest HD and 12 manifest HD subjects were enrolled. NFL and tau levels were correlated. NFL showed strong correlations with all items included in the clinical assessment (for example the total functional capacity (TFC) (r = - 0.70 p < 0.01) and total motor score (TMS) (r = 0.83p < 0.01). Tau showed slightly weaker correlations (eg. TMS (r = 0.67 p < 0.01); TFC (r = - 0.59 p < 0.01)). NFL was significantly correlated with 5-year probability of disease onset, whereas tau was not.
This study strengthens the case for NFL as a useful biomarker of disease stage. NFL was strongly correlated to all evaluated items in the UHDRS assessment. Tau also has a potential for use as a biomarker but correlations to clinical tests are weaker in this study. We suggest that NFL and possibly tau be used in clinical drug trials as biomarkers of disease progression that are potentially influenced by future disease-modifying therapies. |
|---|---|
| AbstractList | Previous studies have suggested cerebrospinal fluid (CSF) levels of neurofilament light (NFL) and total tau are elevated in Huntington's disease (HD) and may be used as markers of disease stage. Biomarkers are needed due to the slow disease progression and the limitations of clinical assessment. This study aims to validate the role of NFL and tau as biomarkers in HD. CSF was obtained from a cohort of HD patients and premanifest HD-mutation carriers. Unified Huntington's Disease Rating Scale (UHDRS) testing was performed on all subjects at the time of sampling. NFL and tau concentrations were determined by ELISA. Spearman correlations were calculated with R version 3.2.3. 11 premanifest HD and 12 manifest HD subjects were enrolled. NFL and tau levels were correlated. NFL showed strong correlations with all items included in the clinical assessment (for example the total functional capacity (TFC) (r = - 0.70 p < 0.01) and total motor score (TMS) (r = 0.83p < 0.01). Tau showed slightly weaker correlations (eg. TMS (r = 0.67 p < 0.01); TFC (r = - 0.59 p < 0.01)). NFL was significantly correlated with 5-year probability of disease onset, whereas tau was not. This study strengthens the case for NFL as a useful biomarker of disease stage. NFL was strongly correlated to all evaluated items in the UHDRS assessment. Tau also has a potential for use as a biomarker but correlations to clinical tests are weaker in this study. We suggest that NFL and possibly tau be used in clinical drug trials as biomarkers of disease progression that are potentially influenced by future disease-modifying therapies. Introduction Previous studies have suggested cerebrospinal fluid (CSF) levels of neurofilament light (NFL) and total tau are elevated in Huntington's disease (HD) and may be used as markers of disease stage. Biomarkers are needed due to the slow disease progression and the limitations of clinical assessment. This study aims to validate the role of NFL and tau as biomarkers in HD. CSF was obtained from a cohort of HD patients and premanifest HD-mutation carriers. Unified Huntington's Disease Rating Scale (UHDRS) testing was performed on all subjects at the time of sampling. NFL and tau concentrations were determined by ELISA. Spearman correlations were calculated with R version 3.2.3. 11 premanifest HD and 12 manifest HD subjects were enrolled. NFL and tau levels were correlated. NFL showed strong correlations with all items included in the clinical assessment (for example the total functional capacity (TFC) (r = - 0.70 p < 0.01) and total motor score (TMS) (r = 0.83p < 0.01). Tau showed slightly weaker correlations (eg. TMS (r = 0.67 p < 0.01); TFC (r = - 0.59 p < 0.01)). NFL was significantly correlated with 5-year probability of disease onset, whereas tau was not. This study strengthens the case for NFL as a useful biomarker of disease stage. NFL was strongly correlated to all evaluated items in the UHDRS assessment. Tau also has a potential for use as a biomarker but correlations to clinical tests are weaker in this study. We suggest that NFL and possibly tau be used in clinical drug trials as biomarkers of disease progression that are potentially influenced by future disease-modifying therapies. Introduction Previous studies have suggested cerebrospinal fluid (CSF) levels of neurofilament light (NFL) and total tau are elevated in Huntington's disease (HD) and may be used as markers of disease stage. Biomarkers are needed due to the slow disease progression and the limitations of clinical assessment. This study aims to validate the role of NFL and tau as biomarkers in HD. Methods CSF was obtained from a cohort of HD patients and premanifest HD-mutation carriers. Unified Huntington's Disease Rating Scale (UHDRS) testing was performed on all subjects at the time of sampling. NFL and tau concentrations were determined by ELISA. Spearman correlations were calculated with R version 3.2.3. Results 11 premanifest HD and 12 manifest HD subjects were enrolled. NFL and tau levels were correlated. NFL showed strong correlations with all items included in the clinical assessment (for example the total functional capacity (TFC) (r = - 0.70 p < 0.01) and total motor score (TMS) (r = 0.83p < 0.01). Tau showed slightly weaker correlations (eg. TMS (r = 0.67 p < 0.01); TFC (r = - 0.59 p < 0.01)). NFL was significantly correlated with 5-year probability of disease onset, whereas tau was not. Conclusion This study strengthens the case for NFL as a useful biomarker of disease stage. NFL was strongly correlated to all evaluated items in the UHDRS assessment. Tau also has a potential for use as a biomarker but correlations to clinical tests are weaker in this study. We suggest that NFL and possibly tau be used in clinical drug trials as biomarkers of disease progression that are potentially influenced by future disease-modifying therapies. Previous studies have suggested cerebrospinal fluid (CSF) levels of neurofilament light (NFL) and total tau are elevated in Huntington's disease (HD) and may be used as markers of disease stage. Biomarkers are needed due to the slow disease progression and the limitations of clinical assessment. This study aims to validate the role of NFL and tau as biomarkers in HD. CSF was obtained from a cohort of HD patients and premanifest HD-mutation carriers. Unified Huntington's Disease Rating Scale (UHDRS) testing was performed on all subjects at the time of sampling. NFL and tau concentrations were determined by ELISA. Spearman correlations were calculated with R version 3.2.3. 11 premanifest HD and 12 manifest HD subjects were enrolled. NFL and tau levels were correlated. NFL showed strong correlations with all items included in the clinical assessment (for example the total functional capacity (TFC) (r = - 0.70 p < 0.01) and total motor score (TMS) (r = 0.83p < 0.01). Tau showed slightly weaker correlations (eg. TMS (r = 0.67 p < 0.01); TFC (r = - 0.59 p < 0.01)). NFL was significantly correlated with 5-year probability of disease onset, whereas tau was not. This study strengthens the case for NFL as a useful biomarker of disease stage. NFL was strongly correlated to all evaluated items in the UHDRS assessment. Tau also has a potential for use as a biomarker but correlations to clinical tests are weaker in this study. We suggest that NFL and possibly tau be used in clinical drug trials as biomarkers of disease progression that are potentially influenced by future disease-modifying therapies. INTRODUCTION: Previous studies have suggested cerebrospinal fluid (CSF) levels of neurofilament light (NFL) and total tau are elevated in Huntington's disease (HD) and may be used as markers of disease stage. Biomarkers are needed due to the slow disease progression and the limitations of clinical assessment. This study aims to validate the role of NFL and tau as biomarkers in HD. METHODS: CSF was obtained from a cohort of HD patients and premanifest HD-mutation carriers. Unified Huntington's Disease Rating Scale (UHDRS) testing was performed on all subjects at the time of sampling. NFL and tau concentrations were determined by ELISA. Spearman correlations were calculated with R version 3.2.3. RESULTS: 11 premanifest HD and 12 manifest HD subjects were enrolled. NFL and tau levels were correlated. NFL showed strong correlations with all items included in the clinical assessment (for example the total functional capacity (TFC) (r = - 0.70 p < 0.01) and total motor score (TMS) (r = 0.83p < 0.01). Tau showed slightly weaker correlations (eg. TMS (r = 0.67 p < 0.01); TFC (r = - 0.59 p < 0.01)). NFL was significantly correlated with 5-year probability of disease onset, whereas tau was not. CONCLUSION: This study strengthens the case for NFL as a useful biomarker of disease stage. NFL was strongly correlated to all evaluated items in the UHDRS assessment. Tau also has a potential for use as a biomarker but correlations to clinical tests are weaker in this study. We suggest that NFL and possibly tau be used in clinical drug trials as biomarkers of disease progression that are potentially influenced by future disease-modifying therapies. Introduction Previous studies have suggested cerebrospinal fluid (CSF) levels of neurofilament light (NFL) and total tau are elevated in Huntington’s disease (HD) and may be used as markers of disease stage. Biomarkers are needed due to the slow disease progression and the limitations of clinical assessment. This study aims to validate the role of NFL and tau as biomarkers in HD. Methods CSF was obtained from a cohort of HD patients and premanifest HD-mutation carriers. Unified Huntington’s Disease Rating Scale (UHDRS) testing was performed on all subjects at the time of sampling. NFL and tau concentrations were determined by ELISA. Spearman correlations were calculated with R version 3.2.3. Results 11 premanifest HD and 12 manifest HD subjects were enrolled. NFL and tau levels were correlated. NFL showed strong correlations with all items included in the clinical assessment (for example the total functional capacity (TFC) (r = - 0.70 p < 0.01) and total motor score (TMS) (r = 0.83p < 0.01). Tau showed slightly weaker correlations (eg. TMS (r = 0.67 p < 0.01); TFC (r = - 0.59 p < 0.01)). NFL was significantly correlated with 5-year probability of disease onset, whereas tau was not. Conclusion This study strengthens the case for NFL as a useful biomarker of disease stage. NFL was strongly correlated to all evaluated items in the UHDRS assessment. Tau also has a potential for use as a biomarker but correlations to clinical tests are weaker in this study. We suggest that NFL and possibly tau be used in clinical drug trials as biomarkers of disease progression that are potentially influenced by future disease-modifying therapies. Previous studies have suggested cerebrospinal fluid (CSF) levels of neurofilament light (NFL) and total tau are elevated in Huntington's disease (HD) and may be used as markers of disease stage. Biomarkers are needed due to the slow disease progression and the limitations of clinical assessment. This study aims to validate the role of NFL and tau as biomarkers in HD.INTRODUCTIONPrevious studies have suggested cerebrospinal fluid (CSF) levels of neurofilament light (NFL) and total tau are elevated in Huntington's disease (HD) and may be used as markers of disease stage. Biomarkers are needed due to the slow disease progression and the limitations of clinical assessment. This study aims to validate the role of NFL and tau as biomarkers in HD.CSF was obtained from a cohort of HD patients and premanifest HD-mutation carriers. Unified Huntington's Disease Rating Scale (UHDRS) testing was performed on all subjects at the time of sampling. NFL and tau concentrations were determined by ELISA. Spearman correlations were calculated with R version 3.2.3.METHODSCSF was obtained from a cohort of HD patients and premanifest HD-mutation carriers. Unified Huntington's Disease Rating Scale (UHDRS) testing was performed on all subjects at the time of sampling. NFL and tau concentrations were determined by ELISA. Spearman correlations were calculated with R version 3.2.3.11 premanifest HD and 12 manifest HD subjects were enrolled. NFL and tau levels were correlated. NFL showed strong correlations with all items included in the clinical assessment (for example the total functional capacity (TFC) (r = - 0.70 p < 0.01) and total motor score (TMS) (r = 0.83p < 0.01). Tau showed slightly weaker correlations (eg. TMS (r = 0.67 p < 0.01); TFC (r = - 0.59 p < 0.01)). NFL was significantly correlated with 5-year probability of disease onset, whereas tau was not.RESULTS11 premanifest HD and 12 manifest HD subjects were enrolled. NFL and tau levels were correlated. NFL showed strong correlations with all items included in the clinical assessment (for example the total functional capacity (TFC) (r = - 0.70 p < 0.01) and total motor score (TMS) (r = 0.83p < 0.01). Tau showed slightly weaker correlations (eg. TMS (r = 0.67 p < 0.01); TFC (r = - 0.59 p < 0.01)). NFL was significantly correlated with 5-year probability of disease onset, whereas tau was not.This study strengthens the case for NFL as a useful biomarker of disease stage. NFL was strongly correlated to all evaluated items in the UHDRS assessment. Tau also has a potential for use as a biomarker but correlations to clinical tests are weaker in this study. We suggest that NFL and possibly tau be used in clinical drug trials as biomarkers of disease progression that are potentially influenced by future disease-modifying therapies.CONCLUSIONThis study strengthens the case for NFL as a useful biomarker of disease stage. NFL was strongly correlated to all evaluated items in the UHDRS assessment. Tau also has a potential for use as a biomarker but correlations to clinical tests are weaker in this study. We suggest that NFL and possibly tau be used in clinical drug trials as biomarkers of disease progression that are potentially influenced by future disease-modifying therapies. |
| Audience | Academic |
| Author | Sundblom, Jimmy Niemelä, Valter Blennow, Kaj Landtblom, Anne-Marie |
| AuthorAffiliation | Centre de Recherche Jean-Pierre Aubert, FRANCE 2 Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Mölndal Campus, Mölndal, Sweden 3 Department of Neuroscience, Neurosurgery, Uppsala University, Uppsala, Sweden 1 Department of Neuroscience, Neurology, Uppsala University, Uppsala, Sweden |
| AuthorAffiliation_xml | – name: 1 Department of Neuroscience, Neurology, Uppsala University, Uppsala, Sweden – name: 3 Department of Neuroscience, Neurosurgery, Uppsala University, Uppsala, Sweden – name: 2 Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Mölndal Campus, Mölndal, Sweden – name: Centre de Recherche Jean-Pierre Aubert, FRANCE |
| Author_xml | – sequence: 1 givenname: Valter orcidid: 0000-0002-2576-9938 surname: Niemelä fullname: Niemelä, Valter – sequence: 2 givenname: Anne-Marie surname: Landtblom fullname: Landtblom, Anne-Marie – sequence: 3 givenname: Kaj surname: Blennow fullname: Blennow, Kaj – sequence: 4 givenname: Jimmy surname: Sundblom fullname: Sundblom, Jimmy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28241046$$D View this record in MEDLINE/PubMed https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-317298$$DView record from Swedish Publication Index https://gup.ub.gu.se/publication/251646$$DView record from Swedish Publication Index |
| BookMark | eNqNk8lu1TAUhiNURAd4AwSRkBBI3Es8xHZYgKoytFKlSlDKClmOc5K45MYXO2bY8RBseL0-Cb5Dq6YqqMoikfP9v4__47OdbPS2hyS5j7IpIhw9P7XB9aqbzuPyNEMcc4ZvJVuoIHjCcEY2Ln1vJtven2ZZTgRjd5JNLDBFGWVbyedjFVLr0h6Cs7Xp1Az6Ie1M0w5nv35_ao1uU-PToYV0Zh2kPphBlR2kpbEz5b6AS-so3w_9YPpmsP3Zrz8-rYwH5eHV3eR2rToP99bvneTj2zfHe_uTw6N3B3u7hxMd6xkmpaiLmueIMyVqpXNCQClaFVxRVdacKF6VUCGhaygySktWIsLyiiJcKI4KTHaShyvfeWe9XCfjJRKcZoTRXETiYEVUVp3KuTOx-J_SKiOXC9Y1UrnB6A4kMAJFgSte5UAFzUqhseZEC81yXJQQvSYrL_8d5qEcuTVhLuNSE6QHiXPEKIv8s3_yr83J7nL3ECSJTSwWpb5cHyaUM6h0bIhT3Ug1_tObVjb2m8wJFkTk0eDJ2sDZrwH8IGfGa-g61YMNy1i4QDnP8E1QLDjJxOIUj66g1-e8phoVozR9bWOJemEqd6kgmDC8rHB6DRWfCmZGxwsdbyKMBU9HgsgM8GNoVPBeHnx4f3P26GTMPr7EtqC6ofW2C4OxvR-DDy435aIb55MUAboCtLPeO6gvEJTJxcCexyUXAyvXAxtlL67IdBywxfYxEdP9X_wX115Ivg |
| CitedBy_id | crossref_primary_10_1038_s43856_021_00065_5 crossref_primary_10_1007_s00415_024_12700_x crossref_primary_10_1016_j_jns_2023_120744 crossref_primary_10_3389_fneur_2021_779890 crossref_primary_10_1016_j_clineuro_2018_09_024 crossref_primary_10_1007_s12035_020_02035_9 crossref_primary_10_3389_fneur_2021_788168 crossref_primary_10_1016_j_jneumeth_2021_109281 crossref_primary_10_3390_sym13030455 crossref_primary_10_1002_mds_29989 crossref_primary_10_1371_journal_pone_0193492 crossref_primary_10_1038_s41380_023_02230_9 crossref_primary_10_1093_brain_awab404 crossref_primary_10_3390_ijms24076051 crossref_primary_10_1186_s13195_019_0574_0 crossref_primary_10_3390_biology14020129 crossref_primary_10_1016_j_electacta_2021_137815 crossref_primary_10_1016_j_parkreldis_2020_04_009 crossref_primary_10_1093_braincomms_fcab054 crossref_primary_10_1126_scitranslmed_aat7108 crossref_primary_10_3390_ijms25020889 crossref_primary_10_1007_s00415_022_11187_8 crossref_primary_10_1016_j_jns_2024_122979 crossref_primary_10_1017_cts_2022_372 crossref_primary_10_1016_S1474_4422_17_30124_2 crossref_primary_10_1002_mds_28391 crossref_primary_10_3390_brainsci10010056 crossref_primary_10_3390_ijms25126295 crossref_primary_10_3233_JHD_170273 crossref_primary_10_37349_ent_2024_00075 crossref_primary_10_3233_JAD_190851 crossref_primary_10_1016_j_mcn_2019_02_004 crossref_primary_10_3389_fneur_2020_580732 crossref_primary_10_3389_fnins_2021_689938 crossref_primary_10_1007_s12035_019_01698_3 crossref_primary_10_2174_1567205017666201203125622 crossref_primary_10_1016_j_parkreldis_2021_04_017 crossref_primary_10_1097_QAD_0000000000003861 crossref_primary_10_3390_ijms23105411 crossref_primary_10_1186_s40035_024_00443_8 crossref_primary_10_1002_mds_28386 crossref_primary_10_1016_j_ebiom_2024_105173 crossref_primary_10_1007_s00415_025_12966_9 |
| Cites_doi | 10.1517/17530059.2012.701205 10.1212/NXI.0000000000000287 10.1016/j.neuron.2015.10.038 10.1046/j.1471-4159.1996.67052013.x 10.1212/WNL.0000000000001491 10.1172/JCI80743 10.1038/nrneurol.2014.24 10.1016/S1474-4422(13)70090-5 10.1016/S0006-8993(03)03219-0 10.1016/0028-3932(68)90038-9 10.1371/journal.pone.0135886 10.1016/j.parkreldis.2008.05.012 10.1002/mds.20979 10.1016/j.parkreldis.2014.12.013 10.1002/mds.26011 10.1111/j.1468-1331.2009.02808.x 10.1111/j.1399-0004.2004.00241.x 10.3233/JHD-160196 10.1212/WNL.0b013e3181a0fe3f 10.1080/01688638708410764 10.1093/brain/aww021 10.1002/mds.870110204 10.1212/WNL.29.1.1 10.31887/DCNS.2016.18.1/pnopoulos 10.1177/1352458513490544 10.1002/ana.410410521 10.1016/j.parkreldis.2011.06.010 10.1186/s13024-016-0130-3 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2017 Public Library of Science 2017 Niemelä et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2017 Niemelä et al 2017 Niemelä et al |
| Copyright_xml | – notice: COPYRIGHT 2017 Public Library of Science – notice: 2017 Niemelä et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2017 Niemelä et al 2017 Niemelä et al |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM ACNBI ADTPV AOWAS D8T DF2 ZZAVC F1U DOA |
| DOI | 10.1371/journal.pone.0172762 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest SciTech Premium Collection Technology Collection Materials Science & Engineering Database ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest SciTech Premium Collection Technology Collection Advanced Technologies & Aerospace Collection Agricultural & Environmental Science Collection ProQuest Central Essentials ProQuest SciTech Premium Collection Natural Science Collection Biological Science Collection ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Materials Science Collection ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection ProQuest Biological Science Collection Agricultural Science Database ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium ProQuest advanced technologies & aerospace journals ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic (New) ProQuest - Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) SWEPUB Uppsala universitet full text SwePub SwePub Articles SWEPUB Freely available online SWEPUB Uppsala universitet SwePub Articles full text SWEPUB Göteborgs universitet DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Engineering Research Database MEDLINE - Academic Agricultural Science Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| DocumentTitleAlternate | Tau or neurofilament light—Which is the more suitable biomarker for Huntington’s disease? |
| EISSN | 1932-6203 |
| ExternalDocumentID | 1874036458 oai_doaj_org_article_e63e992d7d5e4840b8c2c73c8c6529be oai_gup_ub_gu_se_251646 oai_DiVA_org_uu_317298 PMC5328385 4317423471 A483236285 28241046 10_1371_journal_pone_0172762 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: ; |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM 3V. BBORY CGR CUY CVF ECM EIF IPNFZ NPM RIG PMFND 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS RC3 7X8 5PM ACNBI ADTPV AOWAS D8T DF2 ZZAVC F1U PUEGO - 02 AAPBV ABPTK ADACO BBAFP KM |
| ID | FETCH-LOGICAL-c866t-b8f9f75176a8fac533eaa4d97a4abf73a7dbed18cfe9044b6b1365d4129a71923 |
| IEDL.DBID | M48 |
| ISSN | 1932-6203 |
| IngestDate | Fri Nov 26 17:13:45 EST 2021 Wed Aug 27 01:25:57 EDT 2025 Thu Aug 21 06:29:12 EDT 2025 Thu Aug 21 06:54:02 EDT 2025 Thu Aug 21 14:04:23 EDT 2025 Fri Jul 11 02:15:38 EDT 2025 Thu Jul 10 19:05:51 EDT 2025 Fri Jul 25 10:17:36 EDT 2025 Tue Jun 17 21:08:34 EDT 2025 Tue Jun 10 20:21:01 EDT 2025 Fri Jun 27 04:05:04 EDT 2025 Fri Jun 27 04:02:08 EDT 2025 Thu May 22 21:23:31 EDT 2025 Wed Feb 19 02:08:36 EST 2025 Thu Apr 24 22:55:16 EDT 2025 Tue Jul 01 04:29:55 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c866t-b8f9f75176a8fac533eaa4d97a4abf73a7dbed18cfe9044b6b1365d4129a71923 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Conceptualization: JS VN AML KB.Data curation: VN JS.Formal analysis: VN JS AML.Funding acquisition: JS AML VN KB.Investigation: VN JS AML.Methodology: JS VN AML.Project administration: VN JS AML KB.Resources: JS VN KB.Supervision: AML JS.Validation: KB VN JS.Visualization: VN JS AML KB.Writing – original draft: VN JS.Writing – review & editing: JS VN KB AML. Competing Interests: The authors have declared that no competing interests exist. |
| ORCID | 0000-0002-2576-9938 |
| OpenAccessLink | https://doaj.org/article/e63e992d7d5e4840b8c2c73c8c6529be |
| PMID | 28241046 |
| PQID | 1874036458 |
| PQPubID | 1436336 |
| PageCount | e0172762 |
| ParticipantIDs | plos_journals_1874036458 doaj_primary_oai_doaj_org_article_e63e992d7d5e4840b8c2c73c8c6529be swepub_primary_oai_gup_ub_gu_se_251646 swepub_primary_oai_DiVA_org_uu_317298 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5328385 proquest_miscellaneous_1877815702 proquest_miscellaneous_1872873086 proquest_journals_1874036458 gale_infotracmisc_A483236285 gale_infotracacademiconefile_A483236285 gale_incontextgauss_ISR_A483236285 gale_incontextgauss_IOV_A483236285 gale_healthsolutions_A483236285 pubmed_primary_28241046 crossref_primary_10_1371_journal_pone_0172762 crossref_citationtrail_10_1371_journal_pone_0172762 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2017-02-27 |
| PublicationDateYYYYMMDD | 2017-02-27 |
| PublicationDate_xml | – month: 02 year: 2017 text: 2017-02-27 day: 27 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2017 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | N Butters (ref24) 1987; 9 JB Penney Jr. (ref25) 1997; 41 K Blennow (ref28) 1995; 26 M Vagberg (ref29) 2015; 10 LM Byrne (ref5) 2016; 5 LE Rosengren (ref9) 1996; 67 MG Spillantini (ref13) 2013; 12 AL Benton (ref23) 1968; 6 T Vinther-Jensen (ref17) 2016; 3 CA Ross (ref1) 2014; 10 I Shoulson (ref22) 1979; 29 R Reilmann (ref20) 2014; 29 EJ Wild (ref16) 2015; 125 (ref21) 1996; 11 DR Langbehn (ref26) 2004; 65 PC Nopoulos (ref2) 2016; 18 RI Scahill (ref6) 2012; 6 M Gratuze (ref14) 2016; 139 C Cicognola (ref30) 2016; 11 M Banez-Coronel (ref3) 2015; 88 FB Rodrigues (ref19) 2016 CE Teunissen (ref8) 2009; 72 M Axelsson (ref10) 2014; 20 R Constantinescu (ref18) 2011; 17 HD Rosas (ref12) 2006; 21 D Zielonka (ref4) 2015; 21 M Jonsson (ref7) 2010; 17 J Kuhle (ref11) 2015; 84 R Constantinescu (ref15) 2009; 15 N Norgren (ref27) 2003; 987 |
| References_xml | – volume: 6 start-page: 371 issue: 5 year: 2012 ident: ref6 article-title: Biomarkers for Huntington's disease: an update publication-title: Expert opinion on medical diagnostics doi: 10.1517/17530059.2012.701205 – volume: 26 start-page: 231 issue: 3 year: 1995 ident: ref28 article-title: Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? publication-title: Molecular and chemical neuropathology / sponsored by the International Society for Neurochemistry and the World Federation of Neurology and research groups on neurochemistry and cerebrospinal fluid – volume: 3 start-page: e287 issue: 6 year: 2016 ident: ref17 article-title: Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease publication-title: Neurology(R) neuroimmunology & neuroinflammation doi: 10.1212/NXI.0000000000000287 – year: 2016 ident: ref19 article-title: Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease publication-title: Journal of neurochemistry – volume: 88 start-page: 667 issue: 4 year: 2015 ident: ref3 article-title: RAN Translation in Huntington Disease publication-title: Neuron doi: 10.1016/j.neuron.2015.10.038 – volume: 67 start-page: 2013 issue: 5 year: 1996 ident: ref9 article-title: Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF publication-title: Journal of neurochemistry doi: 10.1046/j.1471-4159.1996.67052013.x – volume: 84 start-page: 1639 issue: 16 year: 2015 ident: ref11 article-title: Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis publication-title: Neurology doi: 10.1212/WNL.0000000000001491 – volume: 125 start-page: 1979 issue: 5 year: 2015 ident: ref16 article-title: Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients publication-title: The Journal of clinical investigation doi: 10.1172/JCI80743 – volume: 10 start-page: 204 issue: 4 year: 2014 ident: ref1 article-title: Huntington disease: natural history, biomarkers and prospects for therapeutics publication-title: Nature reviews Neurology doi: 10.1038/nrneurol.2014.24 – volume: 12 start-page: 609 issue: 6 year: 2013 ident: ref13 article-title: Tau pathology and neurodegeneration publication-title: The Lancet Neurology doi: 10.1016/S1474-4422(13)70090-5 – volume: 987 start-page: 25 issue: 1 year: 2003 ident: ref27 article-title: Elevated neurofilament levels in neurological diseases publication-title: Brain research doi: 10.1016/S0006-8993(03)03219-0 – volume: 6 start-page: 53 year: 1968 ident: ref23 article-title: Differential behavioural effects in frontal lobe disease publication-title: Neuropsychologia doi: 10.1016/0028-3932(68)90038-9 – volume: 10 start-page: e0135886 issue: 8 year: 2015 ident: ref29 article-title: Levels and Age Dependency of Neurofilament Light and Glial Fibrillary Acidic Protein in Healthy Individuals and Their Relation to the Brain Parenchymal Fraction publication-title: PloS one doi: 10.1371/journal.pone.0135886 – volume: 15 start-page: 245 issue: 3 year: 2009 ident: ref15 article-title: Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington's disease publication-title: Parkinsonism & related disorders doi: 10.1016/j.parkreldis.2008.05.012 – volume: 21 start-page: 1317 issue: 9 year: 2006 ident: ref12 article-title: Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures publication-title: Movement disorders: official journal of the Movement Disorder Society doi: 10.1002/mds.20979 – volume: 21 start-page: 169 issue: 3 year: 2015 ident: ref4 article-title: Update on Huntington's disease: advances in care and emerging therapeutic options publication-title: Parkinsonism & related disorders doi: 10.1016/j.parkreldis.2014.12.013 – volume: 29 start-page: 1335 issue: 11 year: 2014 ident: ref20 article-title: Diagnostic criteria for Huntington's disease based on natural history publication-title: Movement disorders: official journal of the Movement Disorder Society doi: 10.1002/mds.26011 – volume: 17 start-page: 377 issue: 3 year: 2010 ident: ref7 article-title: Cerebrospinal fluid biomarkers of white matter lesions—cross-sectional results from the LADIS study publication-title: European journal of neurology doi: 10.1111/j.1468-1331.2009.02808.x – volume: 65 start-page: 267 issue: 4 year: 2004 ident: ref26 article-title: A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length publication-title: Clinical genetics doi: 10.1111/j.1399-0004.2004.00241.x – volume: 5 start-page: 1 issue: 1 year: 2016 ident: ref5 article-title: Cerebrospinal Fluid Biomarkers for Huntington's Disease publication-title: Journal of Huntington's disease doi: 10.3233/JHD-160196 – volume: 72 start-page: 1322 issue: 15 year: 2009 ident: ref8 article-title: Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis publication-title: Neurology doi: 10.1212/WNL.0b013e3181a0fe3f – volume: 9 start-page: 479 issue: 5 year: 1987 ident: ref24 article-title: Episodic and semantic memory: a comparison of amnesic and demented patients publication-title: Journal of clinical and experimental neuropsychology: official journal of the International Neuropsychological Society doi: 10.1080/01688638708410764 – volume: 139 start-page: 1014 issue: Pt 4 year: 2016 ident: ref14 article-title: Is Huntington's disease a tauopathy? publication-title: Brain: a journal of neurology doi: 10.1093/brain/aww021 – volume: 11 start-page: 136 issue: 2 year: 1996 ident: ref21 article-title: Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group publication-title: Movement disorders: official journal of the Movement Disorder Society doi: 10.1002/mds.870110204 – volume: 29 start-page: 1 issue: 1 year: 1979 ident: ref22 article-title: Huntington disease: clinical care and evaluation publication-title: Neurology doi: 10.1212/WNL.29.1.1 – volume: 18 start-page: 91 issue: 1 year: 2016 ident: ref2 article-title: Huntington disease: a single-gene degenerative disorder of the striatum publication-title: Dialogues in Clinical Neuroscience doi: 10.31887/DCNS.2016.18.1/pnopoulos – volume: 20 start-page: 43 issue: 1 year: 2014 ident: ref10 article-title: Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis publication-title: Multiple sclerosis (Houndmills, Basingstoke, England) doi: 10.1177/1352458513490544 – volume: 41 start-page: 689 issue: 5 year: 1997 ident: ref25 article-title: CAG repeat number governs the development rate of pathology in Huntington's disease publication-title: Annals of neurology doi: 10.1002/ana.410410521 – volume: 17 start-page: 714 issue: 9 year: 2011 ident: ref18 article-title: Increased levels of total tau protein in the cerebrospinal fluid in Huntington's disease publication-title: Parkinsonism & related disorders doi: 10.1016/j.parkreldis.2011.06.010 – volume: 11 start-page: 65 issue: 1 year: 2016 ident: ref30 article-title: No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF publication-title: Molecular neurodegeneration doi: 10.1186/s13024-016-0130-3 |
| SSID | ssj0053866 |
| Score | 2.4296525 |
| Snippet | Previous studies have suggested cerebrospinal fluid (CSF) levels of neurofilament light (NFL) and total tau are elevated in Huntington's disease (HD) and may... Introduction Previous studies have suggested cerebrospinal fluid (CSF) levels of neurofilament light (NFL) and total tau are elevated in Huntington's disease... Introduction Previous studies have suggested cerebrospinal fluid (CSF) levels of neurofilament light (NFL) and total tau are elevated in Huntington’s disease... INTRODUCTION: Previous studies have suggested cerebrospinal fluid (CSF) levels of neurofilament light (NFL) and total tau are elevated in Huntington's disease... INTRODUCTION:Previous studies have suggested cerebrospinal fluid (CSF) levels of neurofilament light (NFL) and total tau are elevated in Huntington's disease... Introduction Previous studies have suggested cerebrospinal fluid (CSF) levels of neurofilament light (NFL) and total tau are elevated in Huntington’s disease... |
| SourceID | plos doaj swepub pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e0172762 |
| SubjectTerms | Adult Aged Alzheimer's disease Alzheimers disease Axons - metabolism Biological markers Biology and Life Sciences Biomarkers Biomarkers - cerebrospinal fluid Brain research care Care and treatment Cerebrospinal fluid cerebrospinal-fluid biomarkers Clinical trials Cohort Studies Correlation csf Cytoplasmic filaments Diagnosis Disease control Disease Progression Enzyme-Linked Immunosorbent Assay Female Genetic aspects Humans Huntington Disease - cerebrospinal fluid Huntington Disease - diagnosis Huntington Disease - genetics Huntington's disease Huntingtons disease Light Light levels Male Medicine and Health Sciences Middle Aged Multiple sclerosis Mutation natural-history Neurochemistry Neurodegeneration Neurofilament Proteins - cerebrospinal fluid Neurologi Neurology Neurosciences Neurovetenskaper pathology Physiological aspects protein Proteins Science & Technology - Other Topics Studies Tau protein Tau proteins tau Proteins - cerebrospinal fluid Young Adult |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT1wQ5dWlBQwCCoe0G8exkxNaHtWCBEjQlnKyHMfejbTKrjab_8-M442IWFEOXO1xJM_D_kaZ-UzI8zgtcmt5GVkW64iXMYSUK1gE_iLsOEOKcOxG_vxFTC_4p6v06renvrAmrKMH7hR3akVi85yVskwth2ykyAwzMjGZESnLC4unL9x522SqO4MhioUIjXKJjE-DXU5Wy9qeYNYjBRtcRJ6vvz-V91aLZbMLcv5ZOTngF_V30tltciuASTrpNrFPbtj6DtkP4drQV4FT-vVd8vNct3S5pp6-0lXgBvBpuvAsIj_mlZnTqqGABSnW3dKmrTbYUkWxOR_rd9YUsC2dds9KAFo8bmj4s_PmHrk4-3D-bhqFVxUiA0rZREXmcifTWAqdOW0A7lmteZlLzXXhZKJlWViwmXE2H3NeiAIr4UoOwEBLxIP3yV4NejwglGcpj2GUAezkzLHcCebGbpxbx0zB9YgkWxUrEyjH8eWLhfL_0SSkHp2iFBpGBcOMSNSvWnWUG9fIv0Xr9bJImO0HwI1UcCN1nRuNyBO0veq6T_uwVxMOR16CfaYj8sxLIGlGjVU5M902jfr49fIfhL5_GwgdByG3BHUYHTohYE9IxjWQPBpIQuibwfQBeupWK43yDyzij-UMVm69d_f0034aP4qVdrVdtl4GkugEMt2_ysgsTuUYdP-gC4he-5DCc6wbGBE5CJWBeYYzdTX3vOZpAlgXd_WiC6rBkvfV5cRbtG0VYF6Wwx5e7pCbtSsFQ7NWNVYBeBdcPPwfDnJIbjJEdMhmII_I3mbd2keARzfFY3_0_ALkDoqm priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lj9MwELagXLggltcWFjCI5yG7jePEyWlVHquCBEiwu_SyshzHbiNVSWma-_4ILvy9_SXMJG5QRLVwjceRPOOZfBPPfCbkmR-miTE88wzzlcczH1zKpsyD_RKZUYwU4diN_OlzNDnhH6fh1P1wq1xZ5SYmNoE6KzX-Iz9o7o7DM7P4cPnDw1uj8HTVXaFxlVxD6jIs6RLTLuECX44i1y4XCP_AWWd_WRZmH3MfEbHe56hh7e9i82C5KKttwPPv-skey2jzZTq6SW44SEnH7R7YIVdMcYvsOKet6CvHLP36Njk7VjUtV7QhsbQ5bAZ4NV1gfn5x_vP7PNdzmlcUMCHF-lta1fkaW6soNuljHc-KAsalk_Z6CUCNF-e_KurOeA7vkJOj98dvJ567X8HToJi1l8Y2sSL0RaRiqzQAP6MUzxKhuEqtCJTIUgPW09YkI87TKMWauIwDRFACkeFdMihAl7uE8jjkPjxlAEA5syyxEbMjO0qMZTrlakiCjZqlduTjeAfGQjYnagKSkFZZEo0jnXGGxOtmLVvyjX_Iv0ELdrJInd08KFcz6TxRmigwScIykYWGQ3qbxpppEehYRyFLUjMkj9H-su1D7QKAHHMIfgF2nA7J00YC6TMKrM-Zqbqq5Icvp_8h9O1rT-ilE7IlqEMr1xMBa0Jarp7kXk8SgoDuDe_ibt1opZJ_3AVmbnbw9uEn3TC-FGvuClPWjQyk0wHkvJfKiNgPxQh0f691ik77kMxzrCAYEtFzl555-iNFPm8YzsMAUC-u6nnrWL0p7_LTcWPRupaAflkCa3ixRW5WLyU8mtWyMhJgfMSj-5fr4gG5zhC1IWOB2COD9ao2DwFzrtNHTWD5DfTohZA priority: 102 providerName: ProQuest |
| Title | Tau or neurofilament light—Which is the more suitable biomarker for Huntington’s disease? |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28241046 https://www.proquest.com/docview/1874036458 https://www.proquest.com/docview/1872873086 https://www.proquest.com/docview/1877815702 https://pubmed.ncbi.nlm.nih.gov/PMC5328385 https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-317298 https://gup.ub.gu.se/publication/251646 https://doaj.org/article/e63e992d7d5e4840b8c2c73c8c6529be http://dx.doi.org/10.1371/journal.pone.0172762 |
| Volume | 12 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3Nb9MwFLdGd-GCGF8rjGIQn4dUjePEyQFN3VgpSBtorFsvyHISu61UtaVpJLjtj-DCv7e_hPecNFJE-brkYD9b8nt-9u_F74OQp64fR1rz1NHMVQ5PXVApEzMH9kugOyGmCMdo5OOToD_g74f-cIusa7aWDMw2mnZYT2qwnLa_fvm2Dwr_2lZtEO56UHsxn-k22jQCD-VtuJsEquoxr94VQLvt6yWiFidgHa8MpvvdLLXLyub0r07uxmI6zzbB0l-9K2s5SO291btJbpSAk3aLHbJDtvTsFtkpVTqjL8u8069uk89nKqfzJbUpLs0EtgpMTadovV9dfr8YT5IxnWQUECNF71ya5ZMVBl5RDOFHL58lBQRM-0XxCcCUV5c_Mlq-AO3fIYPe0dlh3ymrLzgJMGnlxKGJjPBdEajQqARgoVaKp5FQXMVGeEqksQbZJkZHHc7jIEaPuZQDgFACceNd0pgBL3cJ5aHPXWhlAE85MywyATMd04m0YUnMVZN4azbLpExNjhUyptK-twkwUQpmSRSOLIXTJE41alGk5vgL_QFKsKLFxNq2Yb4cyVJPpQ48HUUsFamvORi_cZiwRHhJmAQ-i2LdJI9Q_rKIUq2OB9nlcDR6GI_aJE8sBSbXmKH3zkjlWSbffTj_B6JPpzWiFyWRmQM7ElVGTMCaMGlXjXKvRglHRFLr3sXduuZKJm0hRnyADmHkegdv7n5cdeOk6JE30_Pc0oCx7YFF_EcaEbq-6ADv7xVKUXEfTH2O_gVNImrqUhNPvWc2Gdv8574HmBhX9axQrNqQN5PzrpVonkvAxiyCNTzfQDfKFxKaRrnMtASQH_Dg_n9uqAfkOkOQhwkOxB5prJa5fggQdRW3yDUxFPAND1389t62yPbB0cnH05b96dOyp9JPZ5qYlw |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKcoALory6UKhBlMchbeI4dnJAVaFUW_pAgm3pBZnEsXdXqjbLZiPErT-CC3-CH9VfwkySDYqoCpde43G0mZe_Wc-DkKdekETG8NQxzIsdnnpgUjZhDuiLMG6ILcKxGnn_QPQO-bvj4HiB_JrXwmBa5dwnlo46zTT-R75ezo7DO7NwY_LVwalReLs6H6FRqcWu-f4NQrb81c4WyHeVse23_Tc9p54q4OhQiJmThDayMvCkiEMba4A7Jo55GsmYx4mVfizTxMBv1tZELueJSDATLOVwMMYS8RC89wq5CgevixYlj5sAD3yHEHV5ni-99Vob1ibZ2KxhrCUFax1_5ZSA5izoTE6y_Dyg-3e-ZquraXkSbt8kN2oISzcrnVskC2Z8iyzWTiKnL-pO1i9vk8_9uKDZlJZNM-0IlA9eTU_w_4Cz0x-fhiM9pKOcAgalmO9L82I0w1Iuik0BMG9oSgFT0141zgJQ6tnpz5zWd0obd8jhpXD-LumMgZdLhPIw4B48ZQB4ObMssoJZ17qRsUwnPO4Sf85mpetm5zhz40SVN3gSgp6KWQqFo2rhdInT7JpUzT7-Qf8aJdjQYqvu8kE2Haja8pURvokilso0MBzC6STUTEtfh1oELEpMl6yg_FVV99o4HLXJwdn6WOHaJU9KCmzXMcZ8oEFc5LnaeX_0H0QfP7SIntdENgN26LiuwYBvwjZgLcrlFiU4Hd1aXkJtnXMlV3_ME3bONfj85cfNMr4Uc_zGJitKGgjffYixL6SRoRdIF3h_rzKKhvssBDTqctgtW-bSEk97ZTwalh3VAx9QNn7VamVYrS1bo6PNUqJFoQBtswi-4dk5dINiouDRoFC5URA2CC7uX8yLFXKt19_fU3s7B7sPyHWGiBG7Jchl0plNC_MQ8O4seVQ6GUq-XLZX-w2P78Nx |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkRAXRHl1oVCDKI9D2o3j2MkBVQulaikURB_0goyT2NuVVptlsxHi1h_Bhb_Cz-kvYSbxBkVUhUuv8TjazMvfrOdByGM_TGJjeOYZ5muPZz6YlE2YB_oiTDfCFuFYjfxuV2wd8DdH4dEc-TWrhcG0yplPrBx1lqf4H_laNTsO78yiNevSIj5sbK6Pv3o4QQpvWmfjNGoV2THfv0H4VrzY3gBZrzC2-Xr_1ZbnJgx4aSTE1EsiG1sZ-lLoyOoUoI_Rmmex1FwnVgZaZomB359aE3c5T0SCWWEZh0NSS8RG8N5L5LIMQh9tTB41wR74ESFcqV4g_TWnGavjfGRWMe6SgrWOwmpiQHMuzI-HeXEW6P07d7PV4bQ6FTevk2sOztJerX8LZM6MbpAF5zAK-sx1tX5-k3ze1yXNJ7RqoGkHoIjwajrE_wZOT358Oh6kx3RQUMCjFHN_aVEOpljWRbFBAOYQTSjga7pVj7YAxHp68rOg7n5p_RY5uBDO3ybzI-DlIqE8CrkPTxmAX84si61gtmu7sbEsTbjukGDGZpW6xuc4f2Ooqts8CQFQzSyFwlFOOB3iNbvGdeOPf9C_RAk2tNi2u3qQT_rKeQFlRGDimGUyCw2H0DqJUpbKII1SEbI4MR2yjPJXdQ1s43xUj4PjDbDatUMeVRTYumOERtDXZVGo7feH_0G097FF9NQR2RzYkWpXjwHfhC3BWpRLLUpwQGlreRG1dcaVQv0xVdg50-Czlx82y_hSzPcbmbysaCCUDyDePpdGRn4ou8D7O7VRNNxnESDTLofdsmUuLfG0V0aD46q7ehgA4savWqkNq7VlY3DYqyRalgqQN4vhG56cQdcvxwoe9UtVGAUhhODi7vm8WCZXwJ-pt9u7O_fIVYbgERsnyCUyP52U5j5A32nyoPIxlHy5aKf2G5Rcx6c |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tau+or+neurofilament+light%E2%80%94Which+is+the+more+suitable+biomarker+for+Huntington%E2%80%99s+disease%3F&rft.jtitle=PloS+one&rft.au=Niemel%C3%A4%2C+Valter&rft.au=Landtblom%2C+Anne-Marie&rft.au=Blennow%2C+Kaj&rft.au=Sundblom%2C+Jimmy&rft.date=2017-02-27&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=12&rft.issue=2&rft.spage=e0172762&rft_id=info:doi/10.1371%2Fjournal.pone.0172762&rft.externalDBID=n%2Fa&rft.externalDocID=10_1371_journal_pone_0172762 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |